• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CSF MTBR-tau243 是阿尔茨海默病中 tau 缠结病理的特异性生物标志物。

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.

机构信息

The Tracy Family SILQ Center, Washington University School of Medicine, St Louis, MO, USA.

Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z. Epub 2023 Jul 13.

DOI:10.1038/s41591-023-02443-z
PMID:37443334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10427417/
Abstract

Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because clinical symptoms are strongly correlated with tau aggregates, drug development and clinical diagnosis need cost-effective and accessible specific fluid biomarkers of tau aggregates; however, recent studies suggest that the fluid biomarkers currently available cannot specifically track tau aggregates. We show that the microtubule-binding region (MTBR) of tau containing the residue 243 (MTBR-tau243) is a new cerebrospinal fluid (CSF) biomarker specific for insoluble tau aggregates and compared it to multiple other phosphorylated tau measures (p-tau181, p-tau205, p-tau217 and p-tau231) in two independent cohorts (BioFINDER-2, n = 448; and Knight Alzheimer Disease Research Center, n = 219). MTBR-tau243 was most strongly associated with tau-positron emission tomography (PET) and cognition, whereas showing the lowest association with amyloid-PET. In combination with p-tau205, MTBR-tau243 explained most of the total variance in tau-PET burden (0.58 ≤ R ≤ 0.75) and the performance in predicting cognitive measures (0.34 ≤ R ≤ 0.48) approached that of tau-PET (0.44 ≤ R ≤ 0.52). MTBR-tau243 levels longitudinally increased with insoluble tau aggregates, unlike CSF p-tau species. CSF MTBR-tau243 is a specific biomarker of tau aggregate pathology, which may be utilized in interventional trials and in the diagnosis of patients. Based on these findings, we propose to revise the A/T/(N) criteria to include MTBR-tau243 as representing insoluble tau aggregates ('T').

摘要

聚集的不溶性 tau 蛋白是阿尔茨海默病的两个定义特征之一。由于临床症状与 tau 聚集物密切相关,因此药物开发和临床诊断需要具有成本效益且易于获得的 tau 聚集物的特异性液体生物标志物;然而,最近的研究表明,目前可用的液体生物标志物不能特异性地追踪 tau 聚集物。我们表明,含有残基 243 的微管结合区(MTBR)的 tau(MTBR-tau243)是一种新的脑脊液(CSF)生物标志物,特异性针对不溶性 tau 聚集物,并将其与其他多个磷酸化 tau 测量值(p-tau181、p-tau205、p-tau217 和 p-tau231)进行了比较在两个独立的队列中(BioFINDER-2,n = 448;和 Knight Alzheimer 疾病研究中心,n = 219)。MTBR-tau243 与 tau 正电子发射断层扫描(PET)和认知能力的相关性最强,而与淀粉样蛋白-PET 的相关性最低。与 p-tau205 相结合,MTBR-tau243 解释了 tau-PET 负担的大部分总方差(0.58 ≤ R ≤ 0.75)和预测认知测量值的性能(0.34 ≤ R ≤ 0.48)接近 tau-PET(0.44 ≤ R ≤ 0.52)。与 CSF p-tau 物种不同,MTBR-tau243 水平随不溶性 tau 聚集物而纵向增加。CSF MTBR-tau243 是 tau 聚集物病理学的特异性生物标志物,可用于干预试验和患者诊断。基于这些发现,我们建议修订 A/T/(N) 标准,将 MTBR-tau243 纳入代表不溶性 tau 聚集物的“T”。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/82194b53732d/41591_2023_2443_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/137053c1fa73/41591_2023_2443_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/45e915c2ee82/41591_2023_2443_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/05f4bce4176f/41591_2023_2443_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/8f450f660728/41591_2023_2443_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/a681e7c15522/41591_2023_2443_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/11b74ad3aa29/41591_2023_2443_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/9df4336cf299/41591_2023_2443_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/59704b71446f/41591_2023_2443_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/3d4bdd151cf9/41591_2023_2443_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/772762fd6575/41591_2023_2443_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/82194b53732d/41591_2023_2443_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/137053c1fa73/41591_2023_2443_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/45e915c2ee82/41591_2023_2443_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/05f4bce4176f/41591_2023_2443_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/8f450f660728/41591_2023_2443_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/a681e7c15522/41591_2023_2443_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/11b74ad3aa29/41591_2023_2443_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/9df4336cf299/41591_2023_2443_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/59704b71446f/41591_2023_2443_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/3d4bdd151cf9/41591_2023_2443_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/772762fd6575/41591_2023_2443_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3752/10427417/82194b53732d/41591_2023_2443_Fig11_ESM.jpg

相似文献

1
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.CSF MTBR-tau243 是阿尔茨海默病中 tau 缠结病理的特异性生物标志物。
Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z. Epub 2023 Jul 13.
2
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease.血浆MTBR-tau243生物标志物可识别阿尔茨海默病中的tau蛋白缠结病理。
Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03617-7.
3
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum.血浆磷酸化tau217与阿尔茨海默病谱系中的记忆缺陷密切相关。
Brain. 2025 Jan 29. doi: 10.1093/brain/awaf033.
4
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
5
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta.载脂蛋白E4(APOE4)对可溶性和不溶性tau蛋白病理的影响主要受β-淀粉样蛋白的影响。
Brain. 2025 Jan 16. doi: 10.1093/brain/awaf016.
6
Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis.磷酸化tau217在检测认知功能受损和未受损人群中阿尔茨海默病病理的诊断准确性:一项系统评价和荟萃分析
Alzheimers Dement. 2025 Feb;21(2):e14458. doi: 10.1002/alz.14458. Epub 2024 Dec 23.
7
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.阿尔茨海默病的高精度血液检测在准确性上可与临床脑脊液检测相媲美或优于后者。
Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21.
8
Disease staging of Alzheimer's disease using a CSF-based biomarker model.采用基于脑脊液生物标志物模型对阿尔茨海默病进行疾病分期。
Nat Aging. 2024 May;4(5):694-708. doi: 10.1038/s43587-024-00599-y. Epub 2024 Mar 21.
9
Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.几丁质酶-3样1蛋白(CHI3L1)基因座影响YKL-40的脑脊液水平。
BMC Neurol. 2016 Nov 10;16(1):217. doi: 10.1186/s12883-016-0742-9.
10
Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion.与阿尔茨海默病表型及轻度认知障碍向阿尔茨海默病转化相关的不同脑脊液α-突触核蛋白聚集谱。
J Prev Alzheimers Dis. 2025 Feb;12(2):100040. doi: 10.1016/j.tjpad.2024.100040. Epub 2025 Jan 3.

引用本文的文献

1
Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.血浆胶质纤维酸性蛋白在阿尔茨海默病连续过程中的调节作用。
Alzheimers Dement. 2025 Sep;21(9):e70626. doi: 10.1002/alz.70626.
2
CSF total tau as a proxy of synaptic degeneration.脑脊液总tau蛋白作为突触退化的替代指标。
Nat Commun. 2025 Aug 29;16(1):8076. doi: 10.1038/s41467-025-63545-5.
3
Plasma tau biomarkers for biological staging of Alzheimer's disease.用于阿尔茨海默病生物学分期的血浆tau生物标志物。

本文引用的文献

1
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease.CSF 中 tau 磷酸化的 T217 和 T205 占有率代表了阿尔茨海默病中淀粉样蛋白和 tau 病理的改进生物标志物。
Nat Aging. 2023 Apr;3(4):391-401. doi: 10.1038/s43587-023-00380-7. Epub 2023 Mar 13.
2
Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment.比较 Tau PET 视觉解读与 Tau PET 定量、脑脊液生物标志物和纵向临床评估。
J Alzheimers Dis. 2023;93(2):765-777. doi: 10.3233/JAD-230032.
3
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads.
Nat Aging. 2025 Aug 22. doi: 10.1038/s43587-025-00951-w.
4
Circulating Biomarkers for the Early Diagnosis of Alzheimer's Disease.用于阿尔茨海默病早期诊断的循环生物标志物
Int J Mol Sci. 2025 Jul 27;26(15):7268. doi: 10.3390/ijms26157268.
5
A manifesto for Alzheimer's disease drug discovery in the era of disease-modifying therapies.疾病修饰疗法时代阿尔茨海默病药物研发宣言。
Mol Neurodegener. 2025 Aug 6;20(1):88. doi: 10.1186/s13024-025-00872-7.
6
Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles.血浆pTau217在评估淀粉样蛋白和tau生物标志物特征方面的潜在效用。
Eur J Nucl Med Mol Imaging. 2025 Aug 6. doi: 10.1007/s00259-025-07457-y.
7
An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer's disease.阿尔茨海默病中淀粉样蛋白、tau蛋白和炎症病理生理学之间关系的综合观点。
Alzheimers Dement. 2025 Aug;21(8):e70404. doi: 10.1002/alz.70404.
8
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.有认知障碍和无认知障碍个体的Tau正电子发射断层扫描(PET)阳性率随年龄、淀粉样蛋白-β状态、载脂蛋白E(APOE)基因型和性别而变化。
Nat Neurosci. 2025 Jul 16. doi: 10.1038/s41593-025-02000-6.
9
Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.神经退行性疾病中靶向小胶质细胞的生物标志物与治疗策略:现状与未来方向
Mol Neurodegener. 2025 Jul 10;20(1):82. doi: 10.1186/s13024-025-00867-4.
10
Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer's disease.阿尔茨海默病中tau蛋白的纵向聚集、萎缩及认知衰退
Alzheimers Dement. 2025 Jul;21(7):e70435. doi: 10.1002/alz.70435.
血浆生物标志物与死后淀粉样斑块和 tau 缠结负荷之间的特定关联。
EMBO Mol Med. 2023 May 8;15(5):e17123. doi: 10.15252/emmm.202217123. Epub 2023 Mar 13.
4
Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels.全球阿尔茨海默病神经病理学严重程度和蓝斑脆弱性影响血浆磷酸化 tau 水平。
Mol Neurodegener. 2022 Dec 27;17(1):85. doi: 10.1186/s13024-022-00578-0.
5
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.在预测有症状的阿尔茨海默病(AD)患者的认知衰退方面,Tau蛋白正电子发射断层扫描(Tau-PET)优于磷酸化Tau蛋白。
Alzheimers Dement. 2023 Jun;19(6):2497-2507. doi: 10.1002/alz.12875. Epub 2022 Dec 14.
6
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.磷酸化 tau 生物标志物与淀粉样 PET 与 tau PET 的关联。
JAMA Neurol. 2023 Feb 1;80(2):188-199. doi: 10.1001/jamaneurol.2022.4485.
7
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring.Aβ42/40、p-tau231 和 p-tau217 在阿尔茨海默病临床试验选择和疾病监测中的作用差异。
Nat Med. 2022 Dec;28(12):2555-2562. doi: 10.1038/s41591-022-02074-w. Epub 2022 Dec 1.
8
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.淀粉样蛋白和 tau 正电子发射断层扫描(PET)阳性、认知正常的个体未来认知能力下降的风险较高。
Nat Med. 2022 Nov;28(11):2381-2387. doi: 10.1038/s41591-022-02049-x. Epub 2022 Nov 10.
9
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease.淀粉样蛋白相关可溶性tau 的增加与早期阿尔茨海默病tau 聚集率和认知能力下降有关。
Nat Commun. 2022 Nov 4;13(1):6635. doi: 10.1038/s41467-022-34129-4.
10
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.早期症状性阿尔茨海默病中 Donanemab 治疗与探索性血浆生物标志物的关联:TRAILBLAZER-ALZ 随机临床试验的二次分析。
JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392.